Tocagen Inc (NASDAQ:TOCA) Receives $15.79 Consensus PT from Brokerages

Shares of Tocagen Inc (NASDAQ:TOCA) have been assigned an average rating of “Buy” from the eleven research firms that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $15.79.

Several analysts have weighed in on TOCA shares. Zacks Investment Research raised Vistra Energy from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Saturday, July 13th. Citigroup set a $14.00 price target on Coty and gave the company a “hold” rating in a research report on Thursday, May 30th. Cantor Fitzgerald reiterated a “buy” rating and set a $37.00 price target on shares of Vocera Communications in a research report on Thursday, April 25th. ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a research report on Monday, May 13th. Finally, Leerink Swann set a $5.00 price target on Tocagen and gave the company a “hold” rating in a research report on Wednesday, May 22nd.

Tocagen stock traded down $0.18 during mid-day trading on Tuesday, hitting $5.69. 102,849 shares of the company’s stock traded hands, compared to its average volume of 179,037. The company has a 50 day moving average price of $5.83. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.05 and a current ratio of 5.05. The firm has a market cap of $135.32 million, a P/E ratio of -2.33 and a beta of 3.92. Tocagen has a one year low of $4.13 and a one year high of $15.80.

Tocagen (NASDAQ:TOCA) last announced its earnings results on Tuesday, May 7th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $2.01 million. Tocagen had a negative return on equity of 108.08% and a negative net margin of 294.74%. Sell-side analysts forecast that Tocagen will post -2.94 earnings per share for the current year.

In other Tocagen news, Director Faheem Hasnain purchased 43,000 shares of the stock in a transaction dated Thursday, May 30th. The shares were acquired at an average price of $4.66 per share, for a total transaction of $200,380.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have bought 53,000 shares of company stock worth $244,880 in the last quarter. 10.90% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Tocagen by 6.2% during the fourth quarter. BlackRock Inc. now owns 1,501,501 shares of the company’s stock valued at $12,327,000 after buying an additional 88,216 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Tocagen by 19.0% during the first quarter. JPMorgan Chase & Co. now owns 453,391 shares of the company’s stock valued at $4,929,000 after purchasing an additional 72,539 shares during the last quarter. 683 Capital Management LLC boosted its position in Tocagen by 650.0% during the fourth quarter. 683 Capital Management LLC now owns 375,000 shares of the company’s stock valued at $3,079,000 after purchasing an additional 325,000 shares during the last quarter. Northern Trust Corp boosted its position in Tocagen by 9.7% during the fourth quarter. Northern Trust Corp now owns 223,113 shares of the company’s stock valued at $1,831,000 after purchasing an additional 19,721 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Tocagen by 24.2% during the fourth quarter. Geode Capital Management LLC now owns 211,795 shares of the company’s stock valued at $1,738,000 after purchasing an additional 41,261 shares during the last quarter. Institutional investors and hedge funds own 34.88% of the company’s stock.

About Tocagen

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Read More: P/E Growth (PEG)

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.